Locked in a Sensipar patent fight, Teva rolled its generic anyway—and then Amgen settled
Amgen has been sweating potential copycats to its blockbuster calcium reducer Sensipar. But thanks to a patent deal with Teva, yet another challenger will have to wait until 2021 to sell its generic knockoff. This deal features a unique wrinkle, though. Teva had already launched its version, according to Bernstein analyst Ronny Gal, costing Amgen tens… Read More »
